Heritage Cannabis launches its premium ArthroCBD softgel capsules in the US market

Heritage Cannabis Holdings Corp (CSE:CANN) (OTCQX:HERTF) (FRA:2UE) has announced the launch of ArthroCBD, an innovative hemp brand created to help people seeking “symptomatic relief.”

Clinically tested ArthroCBD, is a softgel capsule with 25 mg of CBD and 6 mg of Beta caryophyllene. It is formulated using VESIsorb technology, which boosts absorption, compared to other oral CBD products on the market, said the company.

The improved absorption levels result in “rapid onset of action and long-lasting relief,” Heritage Cannabis added. ArthroCBD has all traces of THC removed to avoid the adverse effects people sometimes suffer from other hemp-based products. The new product line is now available on arthrocbd.com.

READ: Heritage Cannabis expands into the US with its 3Fifteen Primo Cannabis partnership

“We are excited to launch our clinically tested ArthroCBD softgel capsules for those seeking daily relief from physical strain. Physicians, pharmacists, and other health care practitioners all want the same thing – to provide the best treatment for patients with the least side effects. ArthroCBD now provides that option with a highly effective hemp-based CBD product,” said Umar Syed, president of medical products at Heritage Cannabis in a statement.

“Carefully formulated CBD with pharmaceutical technology, tested ingredients, and clinical testing to prove product performance is a logical step in the evolution of hemp-based CBD products. Our focus is to finally provide patients and the healthcare community with products based on credible data.”

Heritage Cannabis has over three decades of experience in marketing pharmaceutical and over the counter (OTC) products. The company said the ArthroCBD launch “marks the first of a pipeline of over 7 new medicinal hemp-based CBD product offerings planned by Heritage.”

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive